Goserelin
ApprovedCompleted 3 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Spinobulbar Muscular Atrophy
Conditions
Spinobulbar Muscular Atrophy, Kennedy's Disease
Trial Timeline
Apr 1, 2008 → Nov 1, 2013
NCT ID
NCT00851461About Goserelin
Goserelin is a approved stage product being developed by AstraZeneca for Spinobulbar Muscular Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT00851461. Target conditions include Spinobulbar Muscular Atrophy, Kennedy's Disease.
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00851461 | Approved | Completed |